| 68.4586 0.191 (0.28%) | 11-06 15:41 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.18  |
1-year : | 1.38 |
| Resists | First : | 1.01 |
Second : | 1.19 |
| Pivot price | 0.88 |
|||
| Supports | First : | 0.74 |
Second : | 0.61 |
| MAs | MA(5) : | 0.91 |
MA(20) : | 0.91 |
| MA(100) : | 1.25 |
MA(250) : | 1.54 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 56.1 |
D(3) : | 47.6 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 2.54 | Low : | 0.74 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DNA ] has closed below upper band by 29.9%. Bollinger Bands are 42.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.01 - 1.02 | 1.02 - 1.02 |
| Low: | 0.92 - 0.92 | 0.92 - 0.93 |
| Close: | 0.93 - 0.93 | 0.93 - 0.94 |
The investment seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the Goldman Sachs Human Evolution Index (the "index"). The fund seeks to achieve its investment objective by investing at least 80% of its assets in securities included in its underlying index. The index is designed to deliver exposure to companies with common equity securities listed on exchanges in certain developed markets that may benefit from the development of new knowledge, medicines and technologies for the medical treatment of the human condition, from birth to end-of-life care.
Mon, 09 Nov 2020
Goldman Launches Merged ETF - Yahoo Sports
Tue, 07 May 2019
5 ETFs Targeting a Healthier America - 24/7 Wall St.
Fri, 29 Mar 2019
BNY Mellon Investment Management to rebrand Dreyfus business - Financial Planning
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 1,700 (M) |
| Shares Float | 1,170 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 80.4 (%) |
| Shares Short | 266,530 (K) |
| Shares Short P.Month | 262,240 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.55 |
| Profit Margin | 0 % |
| Operating Margin | -515.6 % |
| Return on Assets (ttm) | -21.9 % |
| Return on Equity (ttm) | -63.1 % |
| Qtrly Rev. Growth | -64.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.14 |
| EBITDA (p.s.) | -0.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -296 (M) |
| Levered Free Cash Flow | -116 (M) |
| PE Ratio | -2.04 |
| PEG Ratio | -0.2 |
| Price to Book value | 1.69 |
| Price to Sales | 6.31 |
| Price to Cash Flow | -5.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|